Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Malaria Vaccine Candidates R78C With Matrix-M™, and the Combination of RH5.1 and R21 With Matrix-M™, in Children Aged 5-36 Months in Burkina Faso

NCT07183371 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT07183371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Malaria Vaccine Candidates R78C With Matrix-M™, and the Combination of RH5.1 and R21 With Matrix-M™, in Children Aged 5-36 Months in Burkina Faso
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2025
Completion date
December 31, 2026
Enrollment
360 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria,falciparum